Net loss widened to $128M for Q2 2026, driven by a 92% increase in R&D expenses as late-stage clinical trials advanced. Cash reserves of $501.9M are expected to fund operations through Q3 2027, but ongoing litigation and market risks remain significant.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.